Equities

Adagio Therapeutics Inc

ADGI:NMQ

Adagio Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.28
  • Today's Change-0.02 / -0.61%
  • Shares traded341.82k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 30 2022 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases. Its product candidate, adintrevimab, for the prevention and treatment of coronavirus disease 2019 (COVID-19), the disease caused by the virus SARS-CoV-2 and its variants. The Company has a clinical program with a Phase I healthy volunteer single ascending-dose escalation study to establish the safety, pharmacokinetics, and serum virus neutralizing antibody titers of adintrevimab. Its Phase II/III global clinical trial, EVADE, evaluates adintrevimab in the prevention of symptomatic COVID-19 in two separate populations: individuals with known exposure to a person with laboratory-confirmed SARS-CoV-2 infection, also known as post-exposure prophylaxis, and individuals who are at increased risk for SARS-CoV-2 infection, also known as pre-exposure prophylaxis.

  • Revenue in USD (TTM)0.00
  • Net income in USD-288.76m
  • Incorporated2020
  • Employees101.00
  • Location
    Adagio Therapeutics Inc1601 Trapelo Road, Suite 178WALTHAM 02451United StatesUSA
  • Phone+1 (781) 819-0080
  • Fax+1 (302) 531-3150
  • Websitehttps://adagiotx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nautilus Biotechnology Inc0.00-57.67m328.58m113.00--0.9395-----0.4642-0.46420.002.810.00----0.00-25.03---25.64--------------0.00-------222.14------
Cango Inc - ADR535.19m19.28m330.20m2.35k20.590.3257--0.6170.11560.11563.737.310.3387--3.94227,644.301.2212.291.7016.6119.7947.463.6046.30----0.188522.6191.0855.29-100.25--49.01--
22nd Century Group Inc33.19m-36.50m332.36m76.00--5.73--10.01-0.2254-0.22540.20630.35230.526110.6320.47436,671.10-57.86-30.31-65.19-33.185.672.90-109.97-78.085.74-6.140.00--10.0920.31-65.44--14.10--
Biomea Fusion Inc0.00-52.08m332.52m51.00--2.02-----1.84-1.840.005.650.00----0.00-44.37---46.74--------------0.00-------680.75------
Humacyte Inc1.34m-26.01m332.70m146.00--3.20--248.10-0.2525-0.25250.0131.01------9,184.93-------------1,939.45-----16.000.3265---15.29--60.20------
Caribou Biosciences Inc10.68m-72.85m337.52m97.00--0.9076--31.62-2.47-2.470.2416.130.0348--7.32110,061.90-23.73---25.78-------682.39------0.00---22.35---95.07------
Tyra Biosciences Inc0.00-36.91m339.52m25.00--1.16-----1.39-1.390.006.980.00----0.00-16.75---17.00--------------0.00-------181.64------
Willdan Group, Inc.366.51m-8.42m355.23m1.56k--1.9839.720.9692-0.6719-0.671928.7413.600.9676--3.36234,940.40-2.220.1833-2.940.266936.8632.88-2.300.1621---2.840.3980.00-9.5211.1141.94--38.60--
Vera Therapeutics Inc0.00-44.98m361.50m18.00--2.69-----2.02-2.020.004.970.00----0.00-41.49---46.59-------------471.790.0354------38.95------
Adagio Therapeutics Inc0.00-288.76m362.14m101.00--0.7878-----3.08-3.080.004.190.00----0.00-88.69---109.60--------------0.00-------247.20------
Qiwi PLC832.36m352.60m364.47m1.90k1.030.4050.96120.43795.655.6513.3514.350.5579--5.58437,163.9023.9213.0539.1629.1857.9356.0042.8626.59----0.2488--1.2618.1356.0447.72-5.5744.28
Aura Biosciences Inc-100.00bn-100.00bn367.80m52.00--2.60----------4.83----------------------------0.00-------53.30------
Aerovate Therapeutics Inc0.00-31.10m377.38m16.00--2.33-----1.32-1.320.006.630.00----0.00-35.14---36.48--------------0.00-------135.41------
Gracell Biotechnologies Inc (ADR)54.63k-63.45m378.14m202.00--1.25--6,921.93-0.9721-0.97210.00084.370.0003----270.44-32.06---34.36-------111,137.20-----403.020.0544-------36.73------
Edgewise Therapeutics Inc0.00-50.66m383.22m38.00--1.47-----1.03-1.030.005.250.00----0.00-17.35---17.80--------------0.00-------150.03------
Vectrus Inc1.81bn36.54m388.27m8.10k10.641.097.330.2153.083.08152.3130.002.05--5.01222,979.304.155.446.658.728.719.042.022.52--6.560.25120.0027.818.4223.7514.0967.52--
Data as of Jun 30 2022. Currency figures normalised to Adagio Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

31.61%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Mar 202215.23m13.88%
The Vanguard Group, Inc.as of 31 Mar 20225.25m4.79%
Slate Path Capital LPas of 31 Mar 20223.74m3.40%
BlackRock Fund Advisorsas of 31 Mar 20222.68m2.44%
683 Capital Management LLCas of 31 Mar 20222.35m2.14%
Redmile Group LLCas of 31 Mar 20221.92m1.75%
Invus Public Equities Advisors LLCas of 31 Mar 20221.00m0.91%
Third Point LLCas of 31 Mar 2022987.11k0.90%
Franklin Advisers, Inc.as of 31 Mar 2022809.05k0.74%
SSgA Funds Management, Inc.as of 31 Mar 2022721.19k0.66%
More ▼
Data from 31 Mar 2022 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.